Indication
Tardive dyskinesia
Tardive dyskinesia is a persistent, potentially irreversible neurological movement disorder caused by prolonged exposure to dopamine receptor–blocking agents, primarily first- and second-generation antipsychotics or certain antiemetic medications. Read more about Tardive dyskinesia
8 drugs 3 manufacturers
Drugs that treat it
Common Tardive dyskinesia therapies.
INGREZZA (valbenazine tosylate)
AUSTEDO TD TITRATN PK (WK 1-2) (deutetrabenazine)
AUSTEDO 12MG START TITR(WK1-4) (deutetrabenazine)
AUSTEDO XR (deutetrabenazine)
AUSTEDO XR TITRATION KT(WK1-4) (deutetrabenazine)
INGREZZA INITIATION PK(TARDIV) (valbenazine tosylate)
INGREZZA SPRINKLE (valbenazine tosylate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonTardive dyskinesia is a persistent, potentially irreversible neurological movement disorder caused by prolonged exposure to dopamine receptor–blocking agents, primarily first- and second-generation antipsychotics or certain antiemetic medications.
It predominantly affects individuals receiving long-term treatment for psychiatric, mood, or gastrointestinal disorders, with higher vulnerability observed in older adults.
Clinically, it is characterized by involuntary, repetitive, purposeless hyperkinetic movements most commonly involving the orofacial musculature—such as tongue protrusion, lip smacking, and grimacing—as well as choreoathetoid movements of the limbs and trunk.
Pathophysiologically, the disorder is thought to result from neuroleptic-induced postsynaptic dopamine receptor supersensitivity and neuroplastic maladaptations within the basal ganglia motor circuitry.
- nih.gov
Tardive dyskinesia is a persistent, potentially irreversible neurological movement disorder caused by prolonged exposure to dopamine receptor–blocking agents, primarily first- and second-generation antipsychotics or certain antiemetic medications It predominantly affects individuals receiving long-term treatment for psychiatric, mood, or gastrointestinal disorders, with higher vulnerability observed in older adults Clinically, it is characterized by involuntary, repetitive, purposeless hyperkine...
- nih.gov
Tardive dyskinesia is a persistent, potentially irreversible neurological movement disorder caused by prolonged exposure to dopamine receptor–blocking agents, primarily first- and second-generation antipsychotics or certain antiemetic medications It predominantly affects individuals receiving long-term treatment for psychiatric, mood, or gastrointestinal disorders, with higher vulnerability observed in older adults Clinically, it is characterized by involuntary, repetitive, purposeless hyperkine...
- tdhelp.org
Tardive dyskinesia is a persistent, potentially irreversible neurological movement disorder caused by prolonged exposure to dopamine receptor–blocking agents, primarily first- and second-generation antipsychotics or certain antiemetic medications Clinically, it is characterized by involuntary, repetitive, purposeless hyperkinetic movements most commonly involving the orofacial musculature—such as tongue protrusion, lip smacking, and grimacing—as well as choreoathetoid movements of the limbs and ...
Personalize your experience
Follow Tardive dyskinesia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.